Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript

Operator

Hello, everyone. Thank you for joining us, and welcome to the Immix Biopharma Inc. Clinical data release. [Operator Instructions] I will now hand the conference over to Dr. Ilya Rachman, Chief Executive Officer. Please go ahead.

Ilya Rachman
Co-Founder, CEO, Chief Scientific Officer & Chairman

Thank you, Hilary, and thank you, everyone, for joining us today. We’re happy to share our clinical and commercial updates today. I’ll be joined today by my colleague, Gabriel Morris, President and Chief Financial Officer; as well as Michael Grabow, Chief Commercial Officer.

Here’s the agenda for our call today. Here’s the agenda for this morning’s call. We will begin with the clinical update followed by a commercial update, and then we’ll proceed to a question-and-answer session.

We will be updating folks today on the progress we’ve made in a disease of light chain Amyloidosis is a disease where normally protective plasma cells residing in all of our bone marrows produce protective antibodies to protect from flus, cold, emerging cancers and other insults. In this disease, instead, they begin to produce toxic antibody fragments called light chains. These light chains circulate throughout the body, and they gum up and destroy every vital organ, starting with the heart, kidney, liver, nerves and others. And unfortunately, patients progress to organ failures, subsequently leading to deaths.